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Abstract
Background: A new staging system recently proposed by the IGCA has demonstrated a better capacity of
stratifying different prognoses for gastric cancer than the 7th edition AJCC staging system (AJCC7). The aim of this
study was to evaluate the efficacy of the IGCA system in Chinese patients.
Methods: Medical records of patients with gastric cancer who received curative surgery in our center from January
2003 to December 2011 were reviewed retrospectively. All the lesions were staged according to both AJCC7 and
IGCA staging systems. Overall survival (OS) of the patients was used as the observation endpoint.
Results: One thousand five hundred twenty-six cases were included in this study. By comparing the AJCC7 system
with the IGCA systems, 395 cases were stratified into different stages, most of which were in stage III. The IGCA
system could better stratify stage IIIB and IIIC patients (5-year OS, 38.1% vs. 29.0%; P = 0.005) than the AJCC7 system
(5-year OS, 38.2% vs. 35.9%; P = 0.148). T3N3bM0, T4aN2M0 and T4aN3bM0 made up 97.5% (385/395) of the stage
shift. T3N3bM0, which was stratified to stage IIIB in the AJCC7 system, showed a significant poorer prognosis than
T4aN2M0 and T4aN3aM0, which were staged to IIIB and IIIC in the same system. The improper staging was revised
in the IGCA staging system.
Conclusions: The IGCA staging system can stratify stage III gastric cancer patients more properly than the AJCC7
system.
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Background
Gastric cancer is the fourth most common cancer and
the second leading cause of cancer-related death [1, 2].
Lymph node (LN) metastasis is the most common
metastatic pattern and the most important factor that
impacts the prognosis of gastric cancer. However, there
is no real consensus over the definition of LN staging.
The Japanese Classification of Gastric Carcinoma
(JCGC) used to assess the metastatic status of LN ac-
cording to the anatomical distribution and this classifi-
cation was widely applied in China because it could
properly depict the extent of lymph node removal of sur-
gery. However, many studies argued that the numeric LN
staging system proposed by the American Joint Commit-
tee on Cancer (AJCC) TNM staging system was simpler
and more practical which demonstrated a better prognos-
tic prediction than the anatomical LN staging pattern [3].
The latest edition of the AJCC is the seventh edition
(AJCC7) published in 2010, which can more precisely pre-
dict the prognosis of gastric cancer after curative surgery
by revising the cutoffs of metastatic lymph node counts in
the previous edition [4, 5]. In this edition, previous N1
stage (metastasis in 1-6 regional LN) is divided into N1
(metastasis in 1-2 regional lymph nodes) and N2 (metasta-
sis in 3-6 regional lymph nodes). Besides, N3 stage is sub-
grouped to N3a (metastasis in 7-15 regional LN) and N3b
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the existing literature [6, 7], a much better prognosis was
observed in patients with N3a stage than those with N3b.
However, the AJCC7 gastric staging system fails to incorp-
orate N3a and N3b into any stage group, which would
impact the prognostic prediction of advanced diseases,
especially for patients with the N3 diseases.
Recently, International Gastric Cancer Association
(IGCA) has proposed a new staging system for gastric
cancer. This system shares the same TNM classification
with the AJCC7 system but introduces pN3a and pN3b
into staging. In this system, all resectable lesions are also
stratified into seven groups from IA to IIIC as is the cases
with the AJCC7 system [7] and each group is classified
according to the number of deaths during five-year period
after surgery. The aim of this study was to evaluate the
suitability of the IGCA staging system for patients with
gastric cancer in China.
Methods
All medical records of gastric cancer patients who re-
ceived curative surgery in our center from January 2003
to December 2011 were reviewed retrospectively. The
criteria for eligibility were histologically proven gastric
adenocarcinoma and R0 resection. Patients with M1
lesions (para-aortic LN, hepatic, peritoneal, or other dis-
tant metastases) were excluded from this study. Patients
who received neoadjuvant therapy were also excluded,
knowing that it may affect the assessments of the resected
specimen and lead to incorrect staging. Demographic
data, clinical features, treatment methods and pathological
findings were investigated based on the medical records.
Each lesion was classified by TNM classification, and then
stratified according to the AJCC7 and IGCA staging sys-
tems independently.
Follow-up was carried out in the outpatient department
and/or through telephone interviews. The observation
endpoint was overall survival (OS). OS was defined as the
duration from surgery to the last follow-up or patient
death. The Kaplan-Meier method and log-rank test were
used to compare OS within patients of different stages. All
tests were two-tailed and P < 0.05 was considered statisti-
cally significant. All statistical analyses were carried out
using SPSS 17.0.
Results
Between January 2003 and December 2011, 1768 con-
secutive cases were collected, of which 242 were
deemed ineligible for the reasons listed in Fig. 1. The
clinical and pathologic features of the included patients
are listed in Table 1. They included 1024 men and 502
women with a median age of 63 (range 22-95) years at
the time of surgery. Patients with early cancers (pT1 stage)
only accounted for 19.5%. The number of retrieved LN
was 23.60 ± 10.59. The prognosis of N3a subgroup
Fig. 1 List of the ineligible reasons in this study
Table 1 Characteristics of included patients
Total number 1526























Distal gastrectomy 1109 (72.7%)
Proximal gastrectomy 193 (12.6%)
Total gastrectomy 224 (14.7%)
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(7–15 involved lymph nodes) was significantly better
than N3b (>15 involved LN) (5-year OS, 42.4% vs.
28.7%, P < 0.001, Fig. 2).
According to the AJCC7 and the IGCA systems, 395
cases were stratified into different stages, and most of
them fell in stage III (Table 2). Only one case of
T1N3b, which was stratified into stage IIB in AJCC7
shifted to stage IIIB in the IGCA system. So the distri-
bution of patients in stage I and II was quite consistent
between the two systems. The survival curves showed
dissimilarity in stage III patients of the two systems
(Fig. 3). Both AJCC7 and IGCA systems demonstrated
a much better OS for IIIA patients than that for IIIB or
IIIC patients (P < 0.001, Fig. 3a, b). However, the IGCA
system could better stratify stage IIIB and IIIC patients
(5-year OS, 38.1% vs. 29.0%; P = 0.005, Fig. 3b) than
the AJCC7 system (5-year OS, 38.2% vs. 35.9%;
P = 0.148, Fig. 3a).
Only 332 patients in this cohort with advanced
diseases had adjuvant chemotherapy in our center. For
these patients, the IGCA system also better stratified the
prognoses of patients in different stages than the AJCC7
system (Additional file 1: Figure S1).
Most cases with a stage shift between the two systems
were in the following three groups: T3N3b, T4aN2 and
T4aN3a (Table 2). The patients in T3N3b had a signifi-
cant shorter OS than those in T4aN2 (P = 0.003, Fig. 4a)
and T4aN3a (P = 0.030, Fig. 4b).
Discussion
The TNM stage is the most important factor used to
instruct treatment strategies in patients with gastric
cancer and indicate the prognosis. The AJCC7 TNM
classification is the latest staging system for gastric can-
cer and contains major modifications compared with
the previous editions. In this edition, N1 stage in the
6th edition is divided into N1 (metastasis in 1-2 re-
gional LN) and N2 (metastasis in 3-6 regional LN)
based on the different prognoses. N2 (metastasis in 7-
15 regional LN) and N3 (metastasis in more than 15 re-
gional LN) in the 6th edition are defined as N3a and
N3b in the AJCC7. It was found in this study that sur-
vival was much better in patients with N3a stage than
that in patients with N3b stage, which is consistent
with the existing literature [6, 8, 9]. This result was also
recognized in the AJCC7 staging system. However, N3a
and N3b were still grouped together as N3 for TNM
staging, which could impact the proper prediction of
the stage-based prognosis.
In contrast, the IGCA took N3a and N3b separately
and established a new staging system in order to better
stratify gastric cancer patients with different progno-
ses. In this staging system, every N3 stage is subdi-
vided into N3a and N3b, whereby patients are divided
into 25 TNM subgroups (Table 2) when M1 was ex-
cluded [7]. However, compared with the AJCC7 sta-
ging system, only seven TNM subgroups (T1N3b,
T2N3b, T3N3b, T4aN2, T4aN3a, T4bN0 and T4bN2)
have stage shift in IGCA system. T2N3b, T3N3b,
T4aN2, T4aN3a, T4bN0 and T4bN2 all fall in stage III
in both AJCC7 and IGCA systems but classified into
different groups. Although T1N3b shifts from stage
IIB in the AJCC7 system to stage IIIB in the IGCA
system, there are rare patients in this subgroup. The
Fig. 2 The distribution of OS curves of N stages
Table 2 Seven groups stratified differently in the two staging systems
N0 (0) N1 (1-2) N2 (3-6) N3a (7-15) N3b (>15)
T1 AJCC7 IA (n = 230) IB (n = 43) IIA (n = 16) IIB (n = 8)
IGCA IIB (n = 7) IIIB (n = 1)
T2 AJCC7 IB (n = 100) IIA (n = 44) IIB (n = 29) IIIA (n = 24)
IGCA IIIA (n = 21) IIIB (n = 3)
T3 AJCC7 IIA (n = 111) IIB (n = 51) IIIA (n = 94) IIIB (n = 87)
IGCA IIIB (n = 62) IIIC (n = 25)
T4a AJCC7 IIB (n = 98) IIIA (n = 103) IIIB (n = 153) IIIC(n = 317)
IGCA IIIA (n = 153) IIIB (n = 207) IIIC (n = 110)
T4b AJCC7 IIIB (n = 5) IIIB (n = 2) IIIC (n = 1) IIIC (n = 10)
IGCA IIIA (n = 5) IIIB (n = 1) IIIC(n = 6) IIIC (n = 4)
Shu et al. BMC Cancer  (2017) 17:238 Page 3 of 6
IGCA system mostly redistributes patients in the three
groups (IIIA, IIIB and IIIC) of stage III.
It was found in this study that the AJCC7 system ex-
cellently separated the survival curves of stage IIIA from
IIIB and IIIC, but failed to discriminate the prognosis of
patients in stage IIIB and stage IIIC. The IGCA systems
precisely stratified the survival probabilities of patients
in IIIA, IIIB and IIIC. This change is obviously due to
the stage shift of the seven TNM subgroups mentioned
above. 395 cases were included in the seven groups and
most of them were stageIII in the AJCC7 or IGCA
systems except for one T1N3b case. Since T1N3b
(n = 1), T2N3b (n = 3), T4bN0 (n = 5) and T4bN2
(n = 1) contained very few cases, the stage shift of the
other three subgroups (T3N3b, T4aN2 and T4aN3a)
played a leading role on the change of survival curves in
stage III. The results of this study indicate that the three
subgroups are not properly staged in the AJCC7 systems.
T3N3b and T4aN2 are both in IIIB, but the 5-year sur-
vival rate of T4aN2 (43.9%) was much better than that
of T3N3b (20.6%). Even T4aN3a in stage IIIC had a
better survival than T3N3b. The improper staging is re-
vised in the IGCA staging system. The 5-year survival
rate of T4aN3a was 39.1%, which perfectly matched that
of stage IIIB (38.1%) in the IGCA system. As a matter of
fact, the 5-year survival rate of T3N3b was even poorer
than stage IIIC disease. Whether this subgroup, together
with T4N3b [6], should be considered as stage IV dis-
eases needs further assessment [10–12].
As mentioned above, the IGCA system shows almost
no revision of stage I and II in AJCC7, suggesting that
the IGCA staging system does not seem to make up for
the defects of AJCC7 on the earlier stages of the
disease. When the IGCA staging system is used, more
regional LN should be harvested, for less than a mini-
mum number of 16 retrieved LN could cause stage mi-
gration by inaccurate LN staging. Besides, an improved
survival outcome was reported to be associated with
more lymph node harvested (>15) [13–15]. However,
the threshold for the harvested LN counts needs to be
further studied.
This retrospective study has certain limitations.
Firstly, although all the patients in this cohort under-
went surgery in our center, many of them did not re-
ceive subsequent standard adjuvant therapy here
owing to their different sources and economic reasons,
which might impact the prognostic assessment. We
Fig. 3 The distribution of OS curves of the different stages grouped by a.AJCC7 staging system; b. IGCA staging system
Fig. 4 Comparison of the survival of T3N3b, T4aN2 and T4aN3a. a.
T3N3b and T4aN2, which were both grouped to III B in AJCC7, were
indicated a different survival, P = 0.003. b. T3N3b still had a poorer
survival than T4aN3a (III C in AJCC7), P = 0.030. The 5-year survival
rate of T3N3b, T4aN2 and T4aN3a was 20.6%, 43.9% and
39.1% respectively
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only analyzed the data of patients who received adju-
vant chemotherapy in our own center. The IGCA sta-
ging system still showed a better performance in
prognostic stratification as indicated in Additional file
1: Figure S1. Secondly, according to the 6th AJCC sta-
ging systems, the lesions in esophagogastric junction
(EGJ) were not distinguished from those in the upper
part of the stomach in this cohort. Although EGJ tumors
were recommended to be staged as esophageal cancers
[16], some current studies had indicated that the
adenocarcinoma of EGJ (Siewert II and Siewert III)
showed similar clinical and pathological characteristics
to the disease derived from stomach and should be
considered as gastric cancer [17, 18].
Conclusions
In summary, after taking pN3a and pN3b as separate
groups, the IGCA system indicates a dissimilarity of
survival curves in stage III patients with comparison to
AJCC7 system. The result of the present study seems to
indicate that the IGCA system is more accurate than
the AJCC7 system in stratifying survival of patients
with gastric cancer in stage III.
Additional file
Additional file 1: Figure: S1. The survival distributions of 332 patients
who received adjuvant chemotherapy in our own center. a The survival
distributions of different stages Grouped by AJCC7 staging system. It was
unable to distinguish the OS difference between III B and III C diseases
(P = 0.958); b The survival distributions of different stages Grouped by
IGCA staging system. The survival of III B and III C diseases were perfectly
stratified (P = 0.003). (TIFF 5298 kb)
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